Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers found that taking the prolonged release version of ropinirole with levodopa significantly reduced daily 'off' time by 2.1 hours compared to the placebo group. Additionally, those taking ropinirole showed improvements in troublesome Parkinson symptoms, quality of life, and motor function.
The NIH is launching a large-scale clinical trial to explore the potential of creatine as a treatment for Parkinson's disease. The study aims to slow the progression of the disease and improve quality of life for patients.
Researchers used massive computer-simulation power to model protein aggregation and its role in Parkinson's and Alzheimer's diseases. They found that beta-synuclein blocks harmful structures caused by alpha-synuclein, offering a potential treatment for debilitating diseases.
A two-year study found that the drug risedronate reduced hip fractures in people with Parkinson disease by three times compared to placebo. Risedronate also increased bone mineral density and decreased biomarkers for bone loss, effectively controlling osteoporosis progression.
A study by Max-Planck-Gesellschaft researchers found that disabling Ret-receptors in mice leads to earlier death of dopaminergic neurons, similar to Parkinson's disease. The loss of these neurons is a hallmark of the disease, and the study suggests that preserving this function may be crucial for preventing neurodegeneration.
Researchers at the University of Kentucky are exploring a novel gene therapy approach using DNA nanoparticles to deliver proteins beneficial to brain cells. This technology has shown potential in rescuing dormant brain cells, causing them to produce dopamine, and improving symptoms in animal models of Parkinson's disease.
Patients with Parkinson's disease who develop the condition at a younger age and have a history of alcohol abuse are more likely to experience pathological gambling as a side effect of dopamine agonist medications. Behavioral characteristics such as impulsivity and risk-taking behavior may also play a role in this increased risk.
A Stanford University study suggests that boosting endocannabinoid levels in the brain may be a new treatment approach for Parkinson's disease. Researchers combined a drug with an experimental compound to trigger improved movement in mice with a condition similar to Parkinson's, showing promising results.
Researchers have developed a new model of Parkinson's disease in fruit flies, confirming the link between dopamine and a mutant form of the parkin protein. The study found that a single copy of the mutation was toxic to dopaminergic neurons, leading to motor dysfunction.
GST pi is a critical enzyme that stands at the crossroads of several biochemical pathways leading to Parkinson's disease. It prevents both externally provoked cell death and internally initiated suicide by blocking the formation of free radicals, which cause cell damage.
The number of individuals with Parkinson's disease is projected to nearly double globally by 2030, with the majority of growth occurring in developing countries in Asia. This growth will be driven by increasing life expectancy and growing economies, which will lead to increased healthcare spending and a greater burden on societies.
A study published in Neurology found that zonisamide significantly improved tremors and dyskinesias in Parkinson disease patients. The medication was effective at 50mg/day, with a nearly 40% improvement in symptoms.
A study by Dr. Xuemei Huang found that participants with lower LDL cholesterol had a 3.5-fold higher occurrence of Parkinson's disease compared to those with higher LDL levels. The results suggest a link between low LDL cholesterol and an increased risk of developing the neurodegenerative disorder.
Researchers have discovered that transplanted neural stem cells can survive, differentiate into neurons, and form synapses with host tissue, potentially offering a new treatment for Parkinson's disease. The study shows promise in reducing the destruction of dopaminergic cells and replacing those lost to the disease.
A groundbreaking study by neurologist Steven Goldman and his team used stem cells to treat Parkinson's disease in rats, achieving a remarkable improvement in symptoms. However, brain tumors appeared due to the stem cells' uncontrolled growth, prompting an urgent need to find solutions.
A study published in Neurology found that people with Parkinson disease were more likely to make safety mistakes during a driving test than those without neurological disorders. The study involved an on-road driving test of participants with mild to moderate Parkinson disease and those of similar age without neurological disorders.
An alliance is being formed in India to conduct Parkinson's disease clinical trials, which will aid in the development of new treatments and slow down disease progression. The initiative aims to bring attention to the condition in India, where only a few neurologists specialize in movement disorders.
The Parkinson Study Group has received a $200,000 grant from the Parkinson's Disease Foundation to fund innovative programs supporting clinical research. The grant will support retrospective data-mining projects and mentorship for young researchers, aiming to accelerate treatment development.
Researchers found that dopamine deficiency in Parkinson's causes loss of muscle control and paralysis due to disruption of coordinated activity in a particular neural circuitry. A new treatment pathway aims to restore this dopamine-regulated circuitry coordination.
Neuroscientists at Duke University Medical Center discovered that critical nerve cells in mice fire all at the same time, overwhelming the brain's ability to control movement. This finding contradicts current theories behind Parkinson's disease and may help develop new therapeutics.
The Phase I trial demonstrated statistically significant clinical efficacy and neuro-imaging results, with patients showing a 25% improvement in Unified Parkinson's Disease Rating Scale scores. PET scan data revealed a significant improvement in brain metabolism on the treated side of the brain compared to the untreated side.
A Phase 1 study of CERE-120, a gene therapy product, demonstrated significant symptom reduction in patients with advanced Parkinson's disease, reducing UPDRS motor 'off' scores by approximately 40%. The treatment also showed promising results in improving 'on' time and reducing 'off' time.
Researchers found that dopamine plays a critical role in regulating sleep and brain activity associated with dreaming. Animal models of Parkinson's disease and schizophrenia exhibited sleep disturbances when dopamine levels were reduced or increased, suggesting a link between dopamine imbalances and sleep problems in these conditions.
Research found that Parkinson's disease patients developing impulse control disorders show increased rates of depression, appetite changes, and irritability compared to those without the disorder. The study identified nine patients with impulse control disorders, including pathological gambling, hypersexuality, and excessive shopping.
A large collaborative effort has made publicly available genetic data for Parkinson's research, providing new opportunities for future studies. The data includes genotypes from hundred of patients and healthy controls, which may help identify common genetic variability that results in minor and moderate risk for disease.
A team of researchers used a sophisticated laser system to gain evidence that neuromelanin, a dark brown pigment accumulating in brains, consists of layers of two other pigments: eumelanin and pheomelanin. This structural arrangement may play a critical role in the neurodegenerative cascade behind Parkinson's disease.
Researchers found accelerated brain changes in people with Parkinson's, while mice exposed to pesticides showed increased oxidative stress and reduced dopamine uptake. Exposure to banned pesticides like dieldrin may increase the risk of developing Parkinson's earlier in life.
UT Southwestern researchers found that blocking tumor necrosis factor, an inflammatory molecule, reduces dopamine neuron death in rats with Parkinson's disease. The study suggests that TNF-dependent inflammation may contribute to the progression of the disease.
Researchers investigated the impact of two copies of the G2019S Parkinson's gene mutation on disease severity. They found no observable differences in symptoms, age of onset, or life expectancy between those with two copies and those with only one copy.
Researchers discovered that dopamine neurons in manganese-exposed animals don't release dopamine when stimulated, suggesting a dysfunctional dopamine system. The study found effects of manganese exposure at high blood concentrations, similar to those in children and adults with environmental or occupational exposure.
The University of Pittsburgh has been designated as an American Parkinson Disease Association Advanced Center for Parkinson's Disease Research. The center will focus on developing early diagnosis methods and understanding iron accumulation in the PD brain. Dr. J. Timothy Greenamyre will direct the center.
Research found that SNCA gene variability is associated with an increased risk of Parkinson disease, explaining approximately 3% of the population's susceptibility. The study also suggests that this variation may be a common factor in the development of the disease.
A large international study provides strong evidence that common genetic variants in the alpha-synuclein gene contribute to Parkinson's disease worldwide. Variability in this gene is associated with a 1.5 times greater risk for the disease, highlighting potential therapies to reduce alpha-synuclein protein production.
Researchers at Mayo Clinic have discovered an association between allergic rhinitis and the development of Parkinson's disease. The study found that people with allergic rhinitis are 2.9 times more likely to develop Parkinson's, highlighting a potential link between inflammation and the disease.
A five-year study by The Parkinson's Institute suggests that nicotine treatment can reduce dopamine cell damage in Parkinson's disease. This protective effect may explain the lower incidence of Parkinson's among smokers, and could potentially lead to new therapy options for early-stage patients.
Researchers at the Montreal Neurological Institute have made a groundbreaking discovery about the parkin gene, which plays a novel role in nerve cell survival. This finding may help identify potential treatment targets for Parkinson's disease and other neurodegenerative disorders.
Researchers have created a new genetic model for Parkinson's disease using mice with a deleted TFAM gene, which mimics the human condition. The study shows that dopamine-producing nerve cells in the brain stem degenerate slowly, similar to humans with Parkinson's disease.
A study found that alterations in the glucocerebrosidase (GBA) gene contribute to dementia with Lewy bodies (DLB), a common neurodegenerative disease. Researchers sequenced DNA from autopsy samples and identified mutations in the GBA gene in nearly 40% of DLB patients.
Researchers found that direct neurologist involvement improves Parkinson's disease symptoms for patients undergoing deep brain stimulation, leading to reduced tremors and medication dosages. This study emphasizes the importance of personalized care by experts in movement disorders and deep brain stimulation.
A recent study found that apathy is a core feature of Parkinson's disease and may occur in up to 51% of patients. Apathy with no depression was also present in 29% of those with Parkinson's disease, highlighting the need for accurate diagnosis and treatment.
A study by Emory University researchers found a connection between developmental exposure to the pesticide dieldrin and an increased risk of developing Parkinson's disease. The study suggests that early life exposures may contribute to neurodegeneration later in life.
A study of 143,325 participants found a strong association between pesticide exposure and Parkinson's disease, with a 70% higher incidence among those exposed. The association was strongest among individuals who used pesticides at home or in gardening, regardless of occupation or sex.
A large cohort study found that chronic pesticide exposure is associated with an increased risk of Parkinson's disease, regardless of occupation or home use. The study suggested that exposure to specific pesticides may be the underlying cause of this increased risk.
Researchers at Whitehead Institute identified a critical biological pathway responsible for Parkinson's symptoms and developed a treatment to repair it. Increasing levels of a transport protein restored normal neurological function in animal models, including fruit flies, worms, and rats with alpha-synuclein-induced Parkinson's symptoms.
Researchers have identified a key defect in ER-to-Golgi trafficking that contributes to alpha-synuclein toxicity, a hallmark of Parkinson's disease. Enhancing this pathway may suppress alpha-synuclein toxicity and protect dopamine-producing neurons.
Researchers identified minocycline's role in blocking poly(ADP-ribose) polymerase-1 (PARP-1), a protein linked to inflammation and cell death. The study suggests minocycline's potential as a treatment for neurodegenerative diseases, but raises concerns about its effects on cancer risk and gender differences.
A study found that REM sleep behavior disorder is a precursor to neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies. Patients with RBD are at increased risk for developing these conditions, which can lead to serious consequences like brain hemorrhages and death.
A new study by Mayo Clinic researchers found that pesticide use increases the risk of Parkinson's disease in men, with a higher likelihood of exposure compared to women. The study matched individuals with Parkinson's disease to those without, assessing exposure via farming occupation or hobbies.
Researchers found that individuals with one mutated parkin gene and one normal gene (heterozygotes) developed Parkinson's disease 11.7 years earlier than those with no mutations, indicating a stronger genetic effect than previously recognized.
Researchers found that individuals with a single copy of the parkin gene mutation exhibit an average age of onset around 43 years old. This discovery challenges current understanding and highlights the need for further investigation into the role of partial parkin gene expression in Parkinson's disease.
Researchers discovered that an aspirin-like drug called sodium para-aminosalicylic acid dramatically reduces symptoms of manganese intoxication. The treatment has been shown to reverse Parkinson-type symptoms even 17 years after initial exposure.
A study identifies Protein Disulphide Isomerase as a marker for neurodegenerative diseases, while also showing its potential as a therapeutic target. The research reveals that NO attacks PDI via S-nitrosylation, altering its function and leading to nerve cell injury.
Researchers found a connection between DJ-1 protein and neurodegeneration in Parkinson's disease, suggesting that environmental toxins may trigger oxidative stress. The study suggests that understanding the role of DJ-1 may lead to the development of new treatments for Parkinson's disease and potentially other neurological disorders.
UB researchers have discovered an agent, L-AP4, that activates group III metabotropic glutamate receptors and reverses damage caused by rotenone. The findings could lead to a new treatment for Parkinson's disease.
Research identifies three estrogen-related gene variants associated with an increased risk of Parkinson's disease in women. The study found that these genetic variations affect 10-20% of the female population and could be used to predict disease risk using a simple blood test.
The new guidelines provide recommendations for early diagnosis, effective therapies, and screening for depression and psychosis. Regular exercise and therapy can also help manage movement difficulties, improving overall quality of life for those with Parkinson disease.
Researchers at MIT have discovered a compound called B2 that promotes the formation of large protein inclusions, which may help stop Huntington's disease progression. The compound also shows promise for treating Parkinson's disease, another neurodegenerative disorder caused by misfolded proteins.
A male-specific gene, SRY, has been found to be linked to the control of physical movement and may contribute to the higher incidence of Parkinson's disease in men. The protein, which determines male gender, was discovered in British scientists in 1990.
Researchers found that male-specific gene SRY is required for normal brain function of dopamine-secreting neurons. This may help explain the higher incidence of Parkinson's disease in males, which exhibits a 3:2 ratio with females.
Researchers found that the SRY gene plays a crucial role in regulating dopamine-producing brain cells, which malfunction in Parkinson's disease. The study suggests that men are more susceptible to the disease due to lower levels of this gene, while women may have an alternative protective mechanism involving estrogens.